A Strategic Team

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies. With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.
They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.
Executive Management Team
A proven record of selecting and developing commercially
successful therapies

Max Krummel, PhD
Founder & Managing Member

Michel Streuli, PhD
Founder, Managing Member, & Chief Executive Officer

Venkataraman “Sriram”, PhD
Founder, Managing Member, & Chief Scientific Officer

Jate Sam, MBA, CLP
Chief Business Officer
Scientific Advisors
A complementary amalgam of cutting-edge scientists with
expertise in basic, clinical, and applied immunology

Adil Daud, MD
Director of Melanoma Clinical Research, HDFCCC, UC San Francisco
Immunotherapy KOL

Ananda Goldrath, PhD
Executive Vice President, Allen Institute for Immunology
Immune Memory KOL

Dan Littman, MD, PhD
Helen L. and Martin S. Kimmel Professor of Molecular Immunology, NYU School of Medicine
Integrated Immune KOL

Richard Locksley, MD
Marion and Herbert Sandler Distinguished Professor, UC San Francisco
Innate Lymphocyte Biology KOL

Leonard G. Presta, PhD
Retired Biotech Veteran
Renowned Antibody & Protein Engineer

Alexis Combes, PhD
Associate Professor, Pathology, UC San Francisco
Immune Archetype KOL
Business Advisors
Seasoned executives with significant venture, operating, M&A and
business development experience

Pete Briger, MBA
Executive Chairman, Fortress Investment Group

Jeff Brody, MBA
Managing Member Emeritus & Co-Founder, Redpoint Ventures

Rekha Hemrajani, MBA
Board Member, ALX Oncology | Bioage | MaxCyte

Forrest Metz, PhD, M. Phil
Founder and Managing Director, Dev Equity

Saira Ramasastry, MS, M. Phil
Founder and Managing Partner, Life Sciences Advisory

Wendy Petka, PhD, JD
Vice President, IP, Horizon Therapeutics